Allergy Therapeutics plc Stock

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:18 2024-04-26 EDT 5-day change 1st Jan Change
2.85 GBX 0.00% Intraday chart for Allergy Therapeutics plc +7.55% +14.00%

Financials

Sales 2022 72.77M 90.9M 124M Sales 2023 59.59M 74.43M 102M Capitalization 7.13M 8.91M 12.18M
Net income 2022 -13M -16.24M -22.2M Net income 2023 -43M -53.71M -73.43M EV / Sales 2022 1.7 x
Net cash position 2022 9.99M 12.47M 17.05M Net Debt 2023 21.14M 26.41M 36.11M EV / Sales 2023 0.47 x
P/E ratio 2022
-9.69 x
P/E ratio 2023
-0.16 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 6.79%
More Fundamentals * Assessed data
Dynamic Chart
1 week+7.55%
Current month-5.00%
1 month-5.00%
3 months+14.00%
6 months+96.55%
Current year+14.00%
More quotes
1 week
2.70
Extreme 2.7
3.00
1 month
2.65
Extreme 2.65
3.20
Current year
1.80
Extreme 1.8
3.20
1 year
0.80
Extreme 0.8
3.90
3 years
0.80
Extreme 0.8
40.50
5 years
0.80
Extreme 0.8
40.50
10 years
0.80
Extreme 0.8
40.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 09-06-30
Director of Finance/CFO - 22-03-31
Chief Tech/Sci/R&D Officer - 03-12-31
Members of the board TitleAgeSince
Director/Board Member 67 17-06-05
Chairman 73 10-09-30
Director/Board Member - 22-12-05
More insiders
Date Price Change Volume
24-04-26 2.85 0.00% 515,871
24-04-25 2.85 0.00% 850,862
24-04-24 2.85 +1.79% 919,062
24-04-23 2.8 -1.75% 948,754
24-04-22 2.85 +7.55% 668,040

Delayed Quote London S.E., April 26, 2024 at 11:35 am

More quotes
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
More about the company